0.50 / AMA PRA Category 1 Credit(s)TM 0.50 / CE for Pharmacists (0.05 CEUs)
This educational initiative is provided by CME Outfitters.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Supported by an educational grant from Genentech.
Although the most common of the restrictive lung diseases, idiopathic pulmonary fibrosis (IPF) is a rare but deadly disease that affects an estimated 6.8 to 42.7 per 100,000 people, with higher rates in those older than 65 years. In the United States, IPF results in approximately 40,000 deaths annually.1
Education to community pulmonologists, radiologists, primary care physicians, and the multidisciplinary team is important to increase knowledge related to recognition and diagnosis. Clinicians need to be aware of when to refer patients with potential IPF to specialty centers with pulmonologists, radiologists, and pathologists specialized in interstitial lung disease (ILD). All providers in the multidisciplinary and multispecialty treatment team need education related to recent ATS/ERS/JRS/ALAT guidelines and mechanisms of action for the approved treatments for IPF.
On January 18, 2017, a CME Outfitters Live and On Demand featured a discussion of baseline data of self-reported gaps in care and skills in recognition, referral, and treatment of IPF. To meet the learning preferences of busy clinicians, the activity has been divided into three short modules.
Module 1: Working Together to Diagnose IPF: Identifying the Signs and Symptoms
Module 2: Title-Working Together to Diagnose IPF: A Multidisciplinary Approach
Module 3: Title-Selecting Appropriate Treatment for Patients With IPF: Applying Guidelines and Clinical Evidence (you are here)
Each module is certified for 0.50 AMA PRA Category 1 Credit(s)TM and 0.50 CE for Pharmacists (0.05 CEUs). We encourage participants to complete all three modules to optimize the learning experience and to gain valuable insights for treating their patients with idiopathic pulmonary fibrosis. _________________________________
Reference 1. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-572.
Pulmonologists, radiologists, primary care physicians, physician assistants, nurse practitioners, nurses, pharmacists and other healthcare providers interested in IPF
At the end of this CME/CE activity, participants should be able to:
Combine information derived from guidelines and studies of newly approved therapies in identifying a treatment approach for the patient with IPF
Conflict Of Interest Disclosure Policy
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Steven D. Nathan, MD, FCCP Medical Director, Lung Transplant Program Director, Advanced Lung Disease Program Inova Fairfax Hospital Professor of Medicine Virginia Commonwealth University, Inova Fairfax Campus Falls Church, VA
Dr. Nathan has disclosed that he receives research support from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc./Roche. He is a member of the speakers bureau for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc./Roche. He is a consultant for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc./Roche.
A. Whitney Brown, MD Director of Clinical Operations Inova Advanced Lung Disease & Transplant Program Assistant Professor of Medicine Virginia Commonwealth University Inova Fairfax Campus Falls Church, VA
Dr. Brown has no disclosures to report.
Jonathan H. Chung, MD Associate Professor of Radiology Associate Section Chief, Thoracic Radiology Director of Thoracic Quality Assurance The University of Chicago Medicine Chicago, IL
Dr. Chung has no disclosures to report.
Accredited Provider Disclosure
The CME Outfitters, LLC staff has nothing to disclose.
Planners' and Managers' Disclosures
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report. Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report. Daniela V. DiBiase, MS (peer reviewer) has no disclosures to report. Jan Perez, CHCP (planning committee) has no disclosures to report. Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
AMA PRA Category 1 Credit(s)TM
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Pharmacists
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.50 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-17-010-H01-P
Activity Type: knowledge-based
Disclosure of Unlabeled Use
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact firstname.lastname@example.org.